Cargando…

Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy

The reported survival rates of patients with acute respiratory distress syndrome (ARDS) caused by human adenovirus (HAdV) pneumonia are poor. The results do not differ much in immunocompetent patients supported by extracorporeal membrane oxygenation (ECMO). We report two immunocompetent patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ha, Sang Ook, Kim, Hyoung Soo, Park, Sunghoon, Jung, Ki-Suck, Jang, Seung Hun, Han, Sang Jin, Kim, Hyun-Sook, Lee, Sun Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095088/ https://www.ncbi.nlm.nih.gov/pubmed/27867816 http://dx.doi.org/10.1186/s40064-016-3571-9

Ejemplares similares

Morbidly obese with severe ARDS: ECMO or no ECMO?
por: Shalaby, Mohammed A.
Publicado: (2017)

The pre-ECMO simplified acute physiology score II as a predictor for mortality in patients with initiation ECMO support at the emergency department for acute circulatory and/or respiratory failure: a retrospective study
por: Kim, Kun Il, et al.
Publicado: (2015)

ECMO for ARDS due to COVID-19
por: Ñamendys-Silva, Silvio A.
Publicado: (2020)

To prone or not to prone ARDS patients on ECMO
por: Roca, Oriol, et al.
Publicado: (2021)

ECMO, ARDS and AH1N1
por: Zangrillo, A
Publicado: (2009)

Brain natriuretic peptide levels predict 6-month mortality in patients with cardiogenic shock who were weaned off extracorporeal membrane oxygenation
por: Kim, Hyoung Soo, et al.
Publicado: (2020)

Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
por: Friedrichson, Benjamin, et al.
Publicado: (2021)

Schedule-Dependent Effect of Epigallocatechin-3-Gallate (EGCG) with Paclitaxel on H460 Cells
por: Park, Sunghoon, et al.
Publicado: (2014)

The advent of ECMO and pumpless extracorporeal lung assist in ARDS
por: Hamid, I A, et al.
Publicado: (2011)

ARDS from miliary tuberculosis successfully treated with ECMO
por: Vesteinsdottir, Edda, et al.
Publicado: (2019)

Successful repeat ECMO in a patient with AIDS and ARDS
por: Horikita, Sho, et al.
Publicado: (2017)

Uninterrupted Continuation of VV-ECMO Without Anticoagulation for 44 Days in COVID-19 ARDS: A Precarious Quandary
por: Patel, Sankalp P., et al.
Publicado: (2022)

Use of ECMO in ARDS: does the EOLIA trial really help?
por: Gattinoni, Luciano, et al.
Publicado: (2018)

Cytokine adsorption during ECMO for COVID-19-related ARDS
por: Shekar, Kiran, et al.
Publicado: (2021)

Veno-venous ECMO as a platform to evaluate lung lavage and surfactant replacement therapy in an animal model of severe ARDS
por: Qaqish, Robert, et al.
Publicado: (2020)

Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
por: Prohaska, Stefanie, et al.
Publicado: (2018)

Successful use of VV-ECMO in a pregnant patient with severe ARDS()()()
por: Carlier, Laurence, et al.
Publicado: (2019)

Herpesviridae reactivation for poor outcome in ARDS patients with ECMO: criminal or witness?
por: Huang, Huixue, et al.
Publicado: (2020)

Characteristics and Outcomes of Severe ARDS Patients Receiving ECMO in Southern Thailand
por: Assanangkornchai, Nawaporn, et al.
Publicado: (2019)

ECMO for Critically Ill COVID-19 with ARDS: A Case Series
por: Rai, D., et al.
Publicado: (2021)

Pheochromocytoma Crisis Presenting With ARDS Successfully Treated With ECMO-Assisted Adrenalectomy
por: Choudhary, Manita, et al.
Publicado: (2021)

Early vvECMO implantation may be associated with lower mortality in ARDS
por: Rosenberger, Peter, et al.
Publicado: (2023)

RESPIRATORY PHYSIOLOGICAL PARAMETERS AND OUTCOMES OF PATIENTS WITH COVID-19 ARDS AND NON-COVID-19 ARDS UNDERGOING ECMO
por: FEDERBUSH, M., et al.
Publicado: (2022)

The Basophil Activation Test Is Safe and Useful for Confirming Drug-Induced Anaphylaxis
por: Kim, Suk Yeon, et al.
Publicado: (2016)

Different characteristics of bloodstream infection during venoarterial and venovenous extracorporeal membrane oxygenation in adult patients
por: Kim, Hyoung Soo, et al.
Publicado: (2021)

Predictors of survival following veno-arterial extracorporeal membrane oxygenation in patients with acute myocardial infarction-related refractory cardiogenic shock: clinical and coronary angiographic factors
por: Kim, Hyoung Soo, et al.
Publicado: (2020)

The use of double lumen cannula for veno-venous ECMO in trauma patients with ARDS
por: Gothner, Martin, et al.
Publicado: (2015)

ECMO for severe ARDS: systematic review and individual patient data meta-analysis
por: Combes, Alain, et al.
Publicado: (2020)

Lower versus higher hemoglobin threshold for transfusion in ARDS patients with and without ECMO
por: Hunsicker, O., et al.
Publicado: (2020)

OUTCOMES OF WHITE VS MINORITY PATIENTS WITH COVID-19 WITH ARDS TREATED WITH ECMO
por: REDDY, RENUKA, et al.
Publicado: (2021)

Case Report: Eculizumab and ECMO Rescue Therapy of Severe ARDS in Goodpasture Syndrome
por: Sobotta, Michael, et al.
Publicado: (2021)

(591) Prolonged V.v.-Ecmo for Covid-19 Ards with Lung Recovery
por: Beckett, A., et al.
Publicado: (2023)

Interhospital transfer of seriously sick ARDS patients using veno-venous Extracorporeal Membrane Oxygenation (ECMO): Concept of an ECMO transport team
por: Starck, Christoph T., et al.
Publicado: (2013)

300 plus days on ECMO – lessons learned
por: Raza, Tasleem
Publicado: (2017)

Efficacy and predictors of response to inhaled corticosteroid treatment for chronic cough
por: Hong, Ji Young, et al.
Publicado: (2019)

Long-term neurocognitive outcome is not worsened by of the use of venovenous ECMO in severe ARDS patients
por: Sylvestre, Aude, et al.
Publicado: (2019)

ARDS and Massive Pulmonary Embolism: The Combined Use of Extracorporeal Membrane Oxygenation (ECMO) with Thrombolytics
por: Dickens, Brett, et al.
Publicado: (2020)

VV-ECMO usage in ARDS due to COVID-19: Clinical, practical and ethical considerations
por: Hoyler, Marguerite M., et al.
Publicado: (2020)

Circulating miRNAs as Promising Biomarkers to Evaluate ECMO Treatment Responses in ARDS Patients
por: Martucci, Gennaro, et al.
Publicado: (2021)

HYPONATREMIA SECONDARY TO VASOPRESSIN IN AN ECMO DEPENDENT PATIENT WITH SEVERE ARDS DUE TO COVID-19
por: HAFEEZ, ZEESHAN, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j4qu5do3hr60pgn1s8jblj32vd